Breaking News Instant updates and real-time market news.

CLVS

Clovis

$59.97

0.27 (0.45%)

, TSRO

Tesaro

$144.31

0.08 (0.06%)

07:31
06/19/17
06/19
07:31
06/19/17
07:31

Clovis jumps, Tesaro slides after release of ARIEL3 study results

Shares of Clovis Oncology (CLVS) are surging after the company this morning announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival, or PFS, by investigator review in each of the three populations studied. In patients with a germline or somatic BRCA mutation, by investigator review, the rucaparib arm successfully achieved statistical significance over the placebo arm for the primary endpoint of PFS with a hazard ratio of 0.23. Janney Capital analyst Debjit Chattopadhyay had said that if Hazard Ratios in g+sBRCA patients were below 0.3, he sees Clovis shares potentially trading up to $85-$100 per share. In such a scenario, he thinks competitor Tesaro (TSRO) could slide to $80-$90. In pre-market trading following the release of the data, Clovis shares are up $20.78, or 34.65%, to $80.75, while Tesaro has dropped $15.44, or 10.7%, to $128.87.

CLVS

Clovis

$59.97

0.27 (0.45%)

TSRO

Tesaro

$144.31

0.08 (0.06%)

  • 30

    Jun

CLVS Clovis
$59.97

0.27 (0.45%)

06/16/17
FBCO
06/16/17
NO CHANGE
Target $88
FBCO
Outperform
Clovis price target raised to $88 from $74 at Credit Suisse
Credit Suisse analyst Alethia Young assumed coverage of Clovis Oncology (CLVS) and raised the firm's price target on the stock to $88 from $74, noting that her 2023 U.S. estimate for rucaparib is $1.3B versus prior coverage's forecast of $700M. Young, who thinks that the PARPi market is big enough that both Clovis and Tesaro (TSRO) can have blockbuster products, believes both companies are likely attractive targets for large global pharma companies, she tells investors. The analyst keeps an Outperform rating on Clovis shares.
06/13/17
06/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Clovis (CLVS) initiated with an Outperform at Leerink. 2. Arconic (ARNC) resumed with an Equal Weight at Morgan Stanley. 3. Tesoro (TSO) reinstated with a Conviction Buy at Goldman Sachs. 4. Golden Ocean (GOGL) initiated with a Buy at Seaport Global. 5. International Seaways (INSW) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/13/17
LEER
06/13/17
INITIATION
Target $85
LEER
Outperform
Clovis initiated with an Outperform at Leerink
Leerink analyst Michael Schmidt started Clovis Oncology with an Outperform rating and $85 price target. Rubraca, currently approved in the U.S. as a therapy in third line ovarian cancer patients, has "significant commercial potential" in other indications not currently adequately reflected in the stock's valuation, the analyst contends. Schmidt estimates Clovis shares could be worth $126 in a bull-case scenario, while the floor valuation of the stock is $33 in a worst-case scenario if ARIL3 outright fails. He also sees the company as a "compelling" takeover target.
06/01/17
RHCO
06/01/17
NO CHANGE
RHCO
SunTrust sees $240/share takeout price for Tesaro
After the Wall Street Journal reported yesterday that Tesaro (TSRO) is exploring a sale, albeit with "modest" interest, SunTrust analyst Peter Lawson says his analysis suggests a $240 per share takeout price for the company. Tesaro closed yesterday up $5.88, or 4%, to $149.31. Acquisitions in the PARP inhibitor space are more likely to happen after Clovis Oncology's (CLVS) ARIEL 3 data at the end of June, as the readout will provide a more apples-to-apples comparison to Tesaro and AstraZeneca (AZN), Lawson tells investors in a research note. His "bull case" points to a $286 per share price for Tesaro and $92 per share price for Clovis. Lawson has Buy ratings on both names. JPMorgan's Cory Kasimov this morning said he likes the setup for Clovis shares into the late June data announcement.
TSRO Tesaro
$144.31

0.08 (0.06%)

06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/09/17
06/09/17
NO CHANGE

Tesaro tells Janney 'no clinical hold, no suspension' in prostate cancer study
After Tesaro (TSRO) shares saw weakness earlier associated with a notice indicating that enrollment was halted in its Johnson & Johnson (JNJ) partnered prostate cancer study, the company told Janney Capital analyst Debjit Chattopadhyay that there is "no clinical hold, no suspension, no safety issues, nothing going on. The first cohort enrolled quickly and we need to see data before starting to enroll the next group - standard trial conduct... JNJ's screening pool was large due to interest, and screen failure rate was lower than expected. Hence, JNJ stopped screening or they would be at risk of enrolling the whole trial before they get to the first data from run in." The analyst, who expect Tesaro shares to be range bound until peer data and regulatory events, keeps a Neutral rating on the stock, which has recovered all of its earlier losses and is now about flat for the session.

TODAY'S FREE FLY STORIES

02:30
01/16/18
01/16
02:30
01/16/18
02:30
General news
FX Update: The dollar has settled above yesterday's trend lows »

FX Update: The dollar has…

01:45
01/16/18
01/16
01:45
01/16/18
01:45
General news
FX Action: USD-JPY has lifted to the upper 110.0s »

FX Action: USD-JPY has…

F

Ford

$13.23

0.07 (0.53%)

, FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

20:06
01/15/18
01/15
20:06
01/15/18
20:06
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

F

Ford

$13.23

0.07 (0.53%)

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

SFTBY

SoftBank

$40.35

-0.705 (-1.72%)

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

TSLA

Tesla

$336.22

-1.73 (-0.51%)

BMWYY

BMW

$36.52

0.835 (2.34%)

TM

Toyota

$137.20

0.29 (0.21%)

GM

General Motors

$44.07

-0.12 (-0.27%)

VLKAY

Volkswagen

$44.34

1.065 (2.46%)

FB

Facebook

$179.37

-8.4 (-4.47%)

AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

AAPL

Apple

$177.09

1.81 (1.03%)

NFLX

Netflix

$221.23

3.99 (1.84%)

VIVHY

Vivendi

$28.42

-1.035 (-3.51%)

BEN

Franklin Resources

$44.53

0.59 (1.34%)

PFE

Pfizer

$36.54

-0.02 (-0.05%)

AMGN

Amgen

$185.04

3.08 (1.69%)

ABBV

AbbVie

$100.34

1.07 (1.08%)

LLY

Eli Lilly

$86.98

0.59 (0.68%)

BMY

Bristol-Myers

$62.81

0.34 (0.54%)

JNJ

Johnson & Johnson

$145.76

0.97 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Jan

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 03

    Feb

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 05

    Mar

  • 18

    Mar

  • 25

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

AAPL

Apple

$177.09

1.81 (1.03%)

19:29
01/15/18
01/15
19:29
01/15/18
19:29
Periodicals
China consumer group seeking answers from Apple on slowing iPhones, Reuters says »

A Chinese consumer group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

TWX

Time Warner

$92.05

0.16 (0.17%)

, CMCSA

Comcast

$42.44

-0.16 (-0.38%)

18:52
01/15/18
01/15
18:52
01/15/18
18:52
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend again »

Sony's (SNE)…

TWX

Time Warner

$92.05

0.16 (0.17%)

CMCSA

Comcast

$42.44

-0.16 (-0.38%)

CMCSK

Comcast

SNE

Sony

$50.03

-0.25 (-0.50%)

FOX

21st Century Fox

$36.37

0.57 (1.59%)

FOXA

21st Century Fox

$36.73

0.53 (1.46%)

LGF.A

Lionsgate

$33.71

0.43 (1.29%)

DIS

Disney

$112.47

1.48 (1.33%)

VIAB

Viacom

$33.76

2.95 (9.57%)

VIA

Viacom

$39.10

3.45 (9.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

FNSR

Finisar

$22.74

0.48 (2.16%)

18:41
01/15/18
01/15
18:41
01/15/18
18:41
Downgrade
Finisar rating change at Goldman Sachs »

Finisar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADTN

Adtran

18:41
01/15/18
01/15
18:41
01/15/18
18:41
Upgrade
Adtran rating change at Goldman Sachs »

Adtran upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

CIEN

Ciena

$21.94

0.06 (0.27%)

18:40
01/15/18
01/15
18:40
01/15/18
18:40
Upgrade
Ciena rating change at Goldman Sachs »

Ciena upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$40.35

-0.705 (-1.72%)

18:36
01/15/18
01/15
18:36
01/15/18
18:36
Periodicals
Auto1 says no need for IPO following SoftBank investment, Reuters reports »

Auto1 said a $561M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$22.07

0.33 (1.52%)

18:32
01/15/18
01/15
18:32
01/15/18
18:32
Hot Stocks
FDA approves Teva's Trisenox injection for Acute Promyelocytic Leukemia »

Teva Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

, GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

18:26
01/15/18
01/15
18:26
01/15/18
18:26
Periodicals
Google relaunching map service in China, Nikkei reports »

Google has relaunched its…

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 18

    Mar

AAPL

Apple

$177.09

1.81 (1.03%)

, TCEHY

Tencent

$56.92

1.565 (2.83%)

18:24
01/15/18
01/15
18:24
01/15/18
18:24
Periodicals
Apple, Tencent reach deal to allow WeChat users dole out tips, WSJ says »

Apple (AAPL) and Tencent…

AAPL

Apple

$177.09

1.81 (1.03%)

TCEHY

Tencent

$56.92

1.565 (2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

RDS.A

Royal Dutch Shell

$70.88

1.04 (1.49%)

, RDS.B

Royal Dutch Shell

$72.70

0.97 (1.35%)

18:20
01/15/18
01/15
18:20
01/15/18
18:20
Periodicals
Shell acquires stake in solar energy company, Axios reports »

Royal Dutch Shell has…

RDS.A

Royal Dutch Shell

$70.88

1.04 (1.49%)

RDS.B

Royal Dutch Shell

$72.70

0.97 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$76.84

1.28 (1.69%)

18:17
01/15/18
01/15
18:17
01/15/18
18:17
Periodicals
Citi to raise pay for women, minorities, Reuters reports »

Citigroup will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

18:10
01/15/18
01/15
18:10
01/15/18
18:10
Periodicals
Fiat Chrysler CEO rules out selling Jeep business, splitting up, WSJ reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$8.08

0.13 (1.64%)

18:06
01/15/18
01/15
18:06
01/15/18
18:06
Hot Stocks
SSR Mining reports production of over 370,000 gold equivalent ounces in 2017 »

SSR Mining said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$87.52

0.59 (0.68%)

17:57
01/15/18
01/15
17:57
01/15/18
17:57
Hot Stocks
Exxon Mobil encounters hydrocarbons onshore Papua New Guinea »

ExxonMobil announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEF

Central Fund of Canada Ltd

$13.68

0.23 (1.71%)

17:56
01/15/18
01/15
17:56
01/15/18
17:56
Hot Stocks
Central Fund of Canada Ltd, Sprott announce plan of arrangement closing date »

Central Fund of Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$39.45

-0.1 (-0.25%)

17:52
01/15/18
01/15
17:52
01/15/18
17:52
Hot Stocks
Adelphia files application for certificate of public convenience and necessity »

Following the conclusion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 25

    Jun

NOK

Nokia

$4.87

0.05 (1.04%)

17:49
01/15/18
01/15
17:49
01/15/18
17:49
Hot Stocks
Nokia wins five-year managed services agreement to manage Optus' network »

Nokia and Optus have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSTR

MicroStrategy

$139.75

1.39 (1.00%)

, AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

17:47
01/15/18
01/15
17:47
01/15/18
17:47
Hot Stocks
MicroStrategy announces rollout of MicroStrategy Partner Program »

MicroStrategy (MSTR)…

MSTR

MicroStrategy

$139.75

1.39 (1.00%)

AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

MSFT

Microsoft

$89.60

1.52 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 31

    Jan

  • 07

    Feb

  • 18

    Mar

DAR

Darling Ingredients

$19.15

0.41 (2.19%)

17:37
01/15/18
01/15
17:37
01/15/18
17:37
Hot Stocks
Darling Ingredients announces new CFO, Chief Administrative Officer »

Darling Ingredients…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AON

Aon plc

$136.55

1.28 (0.95%)

17:34
01/15/18
01/15
17:34
01/15/18
17:34
Hot Stocks
Aon declares quarterly dividend of 36c per share »

Aon announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$20.59

0.39 (1.93%)

17:32
01/15/18
01/15
17:32
01/15/18
17:32
Hot Stocks
KBR assures no disruptions on U.K. defense project »

KBR announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 25

    Jun

TRQ

Turquoise Hill

$3.57

0.06 (1.71%)

17:30
01/15/18
01/15
17:30
01/15/18
17:30
Hot Stocks
Turquoise Hill announces that Oyu Tolgoi received $155M Tax Act »

Turquoise Hill Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.